Evaluation of Pirfenidone Inhalation Solution (AP01) for Progressive Fibrosing Interstitial Lung Diseases, Including Idiopathic Pulmonary Fibrosis

The primary objective of this study is to provide access to **Pirfenidone Solution for Inhalation** (AP01) for patients with **progressive, fibrosing interstitial lung diseases** (ILD), including **idiopathic pulmonary fibrosis** (IPF). This objective is clinically relevant as it allows patients to continue or initiate AP01 therapy until regulatory approval is obtained or the study is terminated. Additionally, the study aims to evaluate the safety outcomes of patients undergoing AP01 therapy, which is crucial for understanding the risk-benefit profile of the treatment in this patient population.

The clinical trial involves a total of **67 participants** diagnosed with **Interstitial Lung Diseases (ILD)**, including but not limited to **idiopathic pulmonary fibrosis (IPF)**. The study population comprises both male and female subjects, all above the age of 18, who are either prior participants in an Avalyn AP01 study or patients with no other treatment options for ILDs. Participants were selected based on their inability to use or tolerate standard treatments such as oral pirfenidone and nintedanib, or due to national formulary restrictions. The trial includes individuals who are part of a vulnerable population, emphasizing the need for careful monitoring and adherence to study protocols. Participants are required to understand and sign an informed consent form and adhere to study requirements, including medication restrictions. Females of childbearing potential must use effective contraception during the study and for 30 days after the last dose of AP01. The sponsor has not provided specific information regarding lifestyle considerations such as diet or physical activity.

The clinical trial is designed to evaluate the safety outcomes of **Pirfenidone** Solution for Inhalation in patients with progressive, fibrosing **interstitial lung diseases** (ILD), including idiopathic pulmonary fibrosis (IPF). This is a Phase 4, non-randomized, open-label study that allows patients to continue or initiate therapy with the investigational product until regulatory approval is obtained or the study is terminated. The trial is expected to run from February 22, 2021, to December 31, 2025, with participant involvement potentially lasting until the study's conclusion or earlier if specific conditions arise.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to assess eligibility based on criteria such as prior participation in an Avalyn AP01 study or lack of alternative treatment options for ILD. Follow-up visits will be scheduled to monitor treatment-emergent adverse events and any treatment-emergent deaths, which are the secondary endpoints of the study. The end-of-study visit will conclude the participant's involvement, provided there are no conditions necessitating early termination, such as withdrawal of consent or significant protocol deviations.

Participants are expected to adhere to the study protocol, including medication restrictions, and females of childbearing potential must use effective contraception during the study and for 30 days after the last dose of AP01. The study may terminate a participant's involvement early if they fail to comply with the protocol, experience intolerable adverse effects, or if the study is discontinued for any reason. The investigational product is administered via inhalation using a nebulizer, with a maximum daily dose of 200 mg. The trial does not include a placebo control, and all participants will receive the active treatment.

The clinical trial involves the administration of **Pirfenidone Solution for Inhalation**, an investigational medication developed by Avalyn Pharma, Inc. This pharmaceutical product is formulated as an **inhalation solution** and is intended for the treatment of progressive, fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis. The active substance in this medication is **pirfenidone**, which is of chemical origin. The solution is administered via **inhalation** using a nebulizer device, specifically the eFlow® nebulizer, which has been certified with a CE mark. The maximum daily dose of pirfenidone is 200 mg, and the treatment period is not explicitly limited, allowing for continuous administration until regulatory approval or study termination. The dosing schedule is designed to ensure consistent delivery of the medication, and participant compliance is monitored throughout the trial.

In addition to the experimental treatment, the study may include non-experimental treatments such as standard-of-care therapy, placebo, or comparator treatments, depending on the specific protocol requirements. These treatments are administered according to established medical guidelines and are used to evaluate the safety and efficacy of the investigational medication. The trial's objective is to allow patients to continue or initiate AP01 therapy while assessing safety outcomes. Compliance with the dosing regimen is closely monitored to ensure the integrity of the study data and participant safety.

The clinical trial aims to assess the efficacy of **Pirfenidone Solution for Inhalation** in the treatment of progressive, fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis. The primary focus of the trial is to allow patients to continue or initiate therapy with AP01 until regulatory approval is obtained or the study is terminated. The efficacy assessment will primarily involve monitoring safety outcomes, as no specific primary efficacy endpoints are applicable. Secondary endpoints include the evaluation of treatment-emergent adverse events and treatment-emergent deaths. These parameters will be collected and analyzed throughout the study duration to determine the safety profile of the treatment. The trial is conducted in Phase 4, indicating a focus on post-marketing surveillance to gather additional information on the drug's safety and efficacy in a broader patient population. The use of the eFlow® nebulizer is integral to the administration of the inhalation solution, ensuring consistent delivery of the medication. The study is designed to adhere to the International Council on Harmonisation Guideline for Good Clinical Practice (ICH-GCP) and local laws, ensuring rigorous data collection and analysis.